Bharat Biotech

What Bharat Biotech does

Bharat Biotech International Limited, founded in 1996 by Dr. Krishna M. Ella and Mrs. Suchitra Ella, is a Hyderabad-headquartered, entirely promoter-owned biotechnology company that develops and manufactures vaccines and bio-therapeutics. It operates one of India's most comprehensive vaccine portfolios with over 20 vaccines spanning COVID-19 (COVAXIN, iNCOVACC), rotavirus (ROTAVAC, ROTAVAC 5D), typhoid (Typbar TCV, Typbar), cholera (Hillchol), Japanese encephalitis (JENVAC), rabies (Indirab), polio (Biopolio), Hib (BioHib), and combination pediatric products (Comvac 4/5), plus biotherapeutic wound-healing brands (REGEN-D, SLVRGEN). The company's technology stack spans five vaccine platforms: inactivated whole virion, live attenuated, polysaccharide conjugate, recombinant DNA, and viral vector, anchored by proprietary HIMAX technology for cesium chloride-free Hepatitis B and a BSL-3 high-containment facility at Genome Valley that produced COVAXIN at 77.8% efficacy. As of July 2025 the company holds 220+ granted global patents with 415 filings, 9-10 billion cumulative doses delivered, manufacturing across six Indian sites, and active distribution to 125+ countries.

Name

Bharat Biotech

Legal name

Bharat Biotech International Limited

Website

https://bharatbiotech.com

Company type

Private

Founded year

1996

Operating status

Operating

Headcount range

1,001–5,000 employees

Short description

Bharat Biotech is a Hyderabad-based, promoter-owned biotechnology company founded in 1996 that develops and manufactures a portfolio of 20+ vaccines and biotherapeutics across five proprietary technology platforms for governments, WHO/UNICEF, and private markets in 125+ countries.

Ownership category

akta.pro rank

Product category

Vaccines & Biotherapeutics

NAICS

Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (3254)

SIC

Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834)

akta.pro primary industry

Travel & Tropical Disease Vaccines (HLAIAEAE)

akta.pro secondary industries

Infectious Disease & Pandemic Preparedness Vaccines (emerging pathogens) (HLAAAEAC), Clinical Development & Regulatory for Vaccines (trials, pharmacovigilance, lot release) (HLAAAEAK), Vaccine Fill-Finish, Packaging & Cold-Chain Formulation (vial/syringe, lyophilization, thermostable) (HLAAAEAJ), Vaccines & Cold-Chain Pharmaceutical Distributors (HLAIAJAG)

Keywords

• Vaccines manufacturing
• Biotherapeutics production
• Cell and gene therapy
• Immunization products
• Recombinant vaccines

Headquarters

HQ city

Hyderabad

HQ country

India

HQ region

Asia

Offices7 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Operations, Personnel, Technology or R&D, Infrastructure, Supply Chain, Marketing or Sales

Revenue model

1. Vaccine Product Sales: Sale of vaccines including COVAXIN, ROTAVAC, Typbar TCV, and other vaccine products to government immunization programs and private markets globally
2. Biotherapeutic Products: Sale of biotherapeutic products including REGEN-D for diabetic foot ulcers and burns, and SLVRGEN for wound healing
3. Technology Licensing: Licensing of proprietary technologies and manufacturing capabilities to international partners
4. CRDMO Services: Contract research, development and manufacturing services through Nucelion Therapeutics for cell and gene therapies

Pricing tiers

Go-to-market motion2 records

Distribution channels3 records

Marketing channels5 records

Core offering

Bharat Biotech manufactures and supplies a portfolio of 20+ vaccines and biotherapeutic products, including COVID-19 vaccines (COVAXIN, iNCOVACC), rotavirus vaccines (ROTAVAC, ROTAVAC 5D), typhoid conjugate vaccine (Typbar TCV), cholera vaccine (Hillchol), rabies, polio, Japanese encephalitis, Hib, hepatitis B, and combination pediatric vaccines, along with wound-healing biotherapeutics (REGEN-D, SLVRGEN). The company also operates a CRDMO subsidiary (Nucelion Therapeutics) providing cell and gene therapy contract manufacturing services. Products are sold to government immunization programs and private healthcare markets across 125+ countries.

Product overview

Bharat Biotech is a Hyderabad-based vaccine and biotherapeutics manufacturer established in 1996, operating as a comprehensive product portfolio company with over 20 vaccines and 4 biotherapeutics. The company's vaccine portfolio spans major disease areas including COVID-19 (COVAXIN®, iNCOVACC®), rotavirus (ROTAVAC®, ROTAVAC 5D®), typhoid (Typbar TCV®, Typbar®), cholera (Hillchol®), Japanese encephalitis (JENVAC®), influenza (HNVAC®), rabies (Indirab®), polio (Biopolio®), Hib (BioHib®), and combination pediatric vaccines (Comvac 4®, Comvac 5®). The hepatitis B franchise includes Revac-B mcf® and Revac-B+® using proprietary HIMAX technology. Biotherapeutics include REGEN-D® 150 and 60 (epidermal growth factors for wound healing), SLVRGEN® (burns treatment), and BIOGIT® (probiotic yeast). The company has expanded into cell and gene therapies through its Nucelion Therapeutics subsidiary, representing a post-pandemic strategic pivot. Bharat Biotech delivers approximately 9-10 billion vaccine doses annually to over 125 countries, with manufacturing facilities in Hyderabad, Ankleshwar, Mallur, and Pune, all conforming to USFDA, KFDA, WHO, and other global regulatory standards.

Differentiator

Problem solved

Functional benefit

Brands

• COVAXIN: India's first indigenous COVID-19 vaccine, developed in collaboration with ICMR-NIV
• iNCOVACC
• ROTAVAC
• ROTAVAC 5D
• Typbar TCV
• Hillchol
• JENVAC
• REGEN-D
• Nucelion Therapeutics

Products and services

• COVAXIN
• iNCOVACC (BBV154)
• ROTAVAC
• ROTAVAC 5D
• Typbar TCV
• Typbar
• Hillchol
• JENVAC
• HNVAC
• Indirab
• Biopolio
• BioHib
• Comvac 5
• Comvac 4
• Revac-B mcf
• Revac-B+
• SLVRGEN
• REGEN-D 150
• REGEN-D 60
• BIOGIT
• Nucelion Therapeutics (CRDMO Services)

Quantifiable outcome

• ROTAVAC 5D reduces moderate-to-severe rotavirus diarrhoea hospitalizations in children under five from 36% to 18%
• +2 more outcomes

Named customers4 records

Segments3 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature6 records

Partnerships

16 partnerships are on record, tiered minor and core.

• Evogene LtdminorStrategic or Co-development Partner · 2 April 2026Key partnership for AI-driven plant genomics targeting sustainable agriculture solutions
• Sagar Defence Engineering Pvt LtdminorStrategic or Co-development Partner · 12 March 2026Bharat Biotech emerged as a key investor supporting maritime innovation project in Andhra Pradesh
• Sapigen Biologix Pvt LtdcoreStrategic or Co-development Partner · 27 February 2026Subsidiary developing large vaccine manufacturing facility in Bhubaneswar, Odisha with Rs 200-250 crore investment
• Tamil Nadu GovernmentcoreOthers · 12 February 2026MoU signed for ₹5,000 crore bio-similars manufacturing facility in Kancheepuram district; government facilitating life sciences park development
• Pandorum TechnologiescoreStrategic or Co-development Partner · 6 January 2026Collaboration with Nucelion Therapeutics (Bharat Biotech subsidiary) to expand manufacturing capabilities for exosome-based therapeutic platform targeting ocular diseases across Asia-Pacific region
• BiofabricoreStrategic or Co-development Partner · 22 December 2025Technology transfer agreement for MTBVAC tuberculosis vaccine to support manufacturing and distribution in over 70 countries as part of India's Phase III clinical trial preparations expected to start in early 2026
• Hilleman LaboratoriescoreStrategic or Co-development Partner · 27 August 2025Partnership for launch of Hillchol oral cholera vaccine in India with plans for WHO prequalification for global distribution
• AlopexxcoreStrategic or Co-development Partner · 11 September 2024Collaboration for development and commercialization of broad-spectrum anti-microbial vaccine AV0328
• GSKcoreStrategic or Co-development Partner · 12 June 2024Partnership to advance development of GSK's Shigella vaccine candidate for severe bacterial diarrhoea; also malaria vaccine RTS,S supply partnership
• Washington University School of MedicinecoreStrategic or Co-development Partner · 23 September 2022Licensing deal for intranasal COVID-19 vaccine technology advancement
• University of Sydney and ExcellGenecoreStrategic or Co-development Partner · 10 May 2022CEPI-funded partnership to develop 'variant-proof' COVID-19 vaccine
• Bilthoven Biologicals (Serum Institute)coreStrategic or Co-development Partner · 2 April 2022Collaboration to produce and supply Oral Polio Vaccines leveraging combined manufacturing capabilities
• OcugencoreChannel Partner/ Reseller/ Distributor · 16 March 2022Co-development and commercialization of COVAXIN for US market; expanded to include Canada
• Precisa MedicamentoscoreChannel Partner/ Reseller/ Distributor · 12 February 2021Supply agreement for COVAXIN to Brazil
• GSK, PATHcoreStrategic or Co-development Partner · 27 January 2021Product transfer agreement to help ensure long-term supply of RTS,S/AS01E malaria vaccine
• CEPI and IVIcoreStrategic or Co-development Partner · 3 June 2020CEPI grant of US$14.1 million for Chikungunya vaccine development in collaboration with Ind-CEPI

Scale indicators6 records

Recent moves9 records

Expansion highlights7 records

Others

• Ocugen: US-based biopharmaceutical partner commercializing COVAXIN in the United States and Canada. Channel partner relationship rather than direct competitor, but provides a useful comparable for routes-to-market in regulated Western geographies.

Direct peers

• Biological E: Hyderabad-based Indian vaccine and biologic manufacturer with strong pediatric immunization portfolio including Japanese encephalitis, DPT, and pentavalent vaccines. Comparable as a peer Indian vaccine producer targeting government tenders and emerging-market supply through WHO PQ.
• Panacea Biotec: New Delhi-based Indian vaccine manufacturer with WHO-prequalified products across polio, DPT, and combination pediatric vaccines. Direct competitor for Indian government immunization contracts and emerging-market tenders with overlapping product portfolio.
• Indian Immunologicals: Hyderabad-based Indian vaccine manufacturer (National Dairy Development Board subsidiary) producing rabies, pediatric, and animal vaccines. Direct peer in Indian government immunization supply and rabies market where Bharat Biotech's Indirab competes.
• Serum Institute of India: World's largest vaccine manufacturer by doses, headquartered in Pune, India. Direct competitor across polio, rotavirus, HPV, measles, and pandemic vaccines, supplying UNICEF and GAVI at global scale. Bharat Biotech and SII compete head-to-head for Indian government immunization contracts and WHO PQ supply positions.

Broad incumbents

• GSK: Global vaccine major with established portfolio across pediatric, travel, and adult vaccines including Shigella and RTS,S malaria — both of which are partnered with Bharat Biotech. Broad incumbent serving overlapping disease areas but with much wider geographic and product reach.
• Sanofi Pasteur: Global vaccines division of Sanofi with deep portfolio across pediatric (Hexaxim), influenza, travel, and rabies vaccines. Broader incumbent competitor in higher-margin travel and adult segments; co-markets Shanchol oral cholera vaccine in markets where Bharat Biotech's Hillchol competes.

Emerging players

• Sinovac Biotech: Chinese vaccine manufacturer with WHO-prequalified COVID-19, influenza, and hepatitis vaccines targeting emerging markets. Comparable as an emerging-market vaccine producer competing for WHO PQ supply positions and developing-world immunization tenders.
• Hilleman Laboratories: Singapore-based vaccine developer co-founded by MSD and Wellcome Trust, partnering with Bharat Biotech on Hillchol oral cholera vaccine. Niche player focused on affordable vaccines for developing countries, with overlapping tropical-disease R&D priorities.
• Biofabri: Spanish biopharmaceutical manufacturer that developed MTBVAC tuberculosis vaccine and signed a technology transfer agreement with Bharat Biotech for manufacturing and distribution in 70+ countries. Specialized vaccine developer with overlapping TB pipeline focus.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks5 records

Key highlights7 records

Customer concentration

• Xx.com/bharatbiotechlt
• Facebookfacebook.com/bharatbiotech
• LinkedInlinkedin.com/company/bharat-biotech-international-limited

Compliance8 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles6 records

Subsidiaries2 records

Funding overview

Funding rounds3 records

Investors3 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Investments2 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Bharat Biotech